Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Mar 14;92(6):2384–2387. doi: 10.1073/pnas.92.6.2384

Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1.

K A McGlynn 1, E A Rosvold 1, E D Lustbader 1, Y Hu 1, M L Clapper 1, T Zhou 1, C P Wild 1, X L Xia 1, A Baffoe-Bonnie 1, D Ofori-Adjei 1, et al.
PMCID: PMC42488  PMID: 7892276

Abstract

Aflatoxin B1 (AFB1) has been postulated to be a hepatocarcinogen in humans, possibly by causing p53 mutations at codon 249. AFB1 is metabolized via the phase I and II detoxification pathways; hence, genetic variation at those loci may predict susceptibility to the effects of AFB1. To test this hypothesis, genetic variation in two AFB1 detoxification genes, epoxide hydrolase (EPHX) and glutathione S-transferase M1 (GSTM1), was contrasted with the presence of serum AFB1-albumin adducts, the presence of hepatocellular carcinoma (HCC), and with p53 codon 249 mutations. Mutant alleles at both loci were significantly overrepresented in individuals with serum AFB1-albumin adducts in a cross-sectional study. Mutant alleles of EPHX were significantly overrepresented in persons with HCC, also in a case-control study. The relationship of EPHX to HCC varied by hepatitis B surface antigen status and indicated that a synergistic effect may exist. p53 codon 249 mutations were observed only among HCC patients with one or both high-risk genotypes. These results indicate that individuals with mutant genotypes at EPHX and GSTM1 may be at greater risk of developing AFB1 adducts, p53 mutations, and HCC when exposed to AFB1. Hepatitis B carriers with the high-risk genotypes may be an even greater risk than carriers with low-risk genotypes. These findings support the existence of genetic susceptibility in humans to the environmental carcinogen AFB1 and indicate that there is a synergistic increase in risk of HCC with the combination of hepatitis B virus infection and susceptible genotype.

Full text

PDF
2384

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguilar F., Hussain S. P., Cerutti P. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8586–8590. doi: 10.1073/pnas.90.18.8586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Board P., Coggan M., Johnston P., Ross V., Suzuki T., Webb G. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther. 1990;48(3):357–369. doi: 10.1016/0163-7258(90)90054-6. [DOI] [PubMed] [Google Scholar]
  3. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991 Apr 4;350(6317):429–431. doi: 10.1038/350429a0. [DOI] [PubMed] [Google Scholar]
  4. Brockmöller J., Kerb R., Drakoulis N., Nitz M., Roots I. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res. 1993 Mar 1;53(5):1004–1011. [PubMed] [Google Scholar]
  5. Buetow K. H., Sheffield V. C., Zhu M., Zhou T., Shen F. M., Hino O., Smith M., McMahon B. J., Lanier A. P., London W. T. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9622–9626. doi: 10.1073/pnas.89.20.9622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Comstock K. E., Sanderson B. J., Claflin G., Henner W. D. GST1 gene deletion determined by polymerase chain reaction. Nucleic Acids Res. 1990 Jun 25;18(12):3670–3670. doi: 10.1093/nar/18.12.3670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Foster P. L., Eisenstadt E., Miller J. H. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci U S A. 1983 May;80(9):2695–2698. doi: 10.1073/pnas.80.9.2695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hassett C., Aicher L., Sidhu J. S., Omiecinski C. J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet. 1994 Mar;3(3):421–428. doi: 10.1093/hmg/3.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hayward N. K., Walker G. J., Graham W., Cooksley E. Hepatocellular carcinoma mutation. Nature. 1991 Aug 29;352(6338):764–764. doi: 10.1038/352764a0. [DOI] [PubMed] [Google Scholar]
  10. Hosono S., Chou M. J., Lee C. S., Shih C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene. 1993 Feb;8(2):491–496. [PubMed] [Google Scholar]
  11. Hsia C. C., Kleiner D. E., Jr, Axiotis C. A., Di Bisceglie A., Nomura A. M., Stemmermann G. N., Tabor E. Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J Natl Cancer Inst. 1992 Nov 4;84(21):1638–1641. doi: 10.1093/jnci/84.21.1638. [DOI] [PubMed] [Google Scholar]
  12. Hsu I. C., Metcalf R. A., Sun T., Welsh J. A., Wang N. J., Harris C. C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991 Apr 4;350(6317):427–428. doi: 10.1038/350427a0. [DOI] [PubMed] [Google Scholar]
  13. Knudson A. G. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914–10921. doi: 10.1073/pnas.90.23.10914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kress S., Jahn U. R., Buchmann A., Bannasch P., Schwarz M. p53 Mutations in human hepatocellular carcinomas from Germany. Cancer Res. 1992 Jun 1;52(11):3220–3223. [PubMed] [Google Scholar]
  15. Li D., Cao Y., He L., Wang N. J., Gu J. R. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis. 1993 Feb;14(2):169–173. doi: 10.1093/carcin/14.2.169. [DOI] [PubMed] [Google Scholar]
  16. Liu Y. H., Taylor J., Linko P., Lucier G. W., Thompson C. L. Glutathione S-transferase mu in human lymphocyte and liver: role in modulating formation of carcinogen-derived DNA adducts. Carcinogenesis. 1991 Dec;12(12):2269–2275. doi: 10.1093/carcin/12.12.2269. [DOI] [PubMed] [Google Scholar]
  17. McCabe E. R. Utility of PCR for DNA analysis from dried blood spots on filter paper blotters. PCR Methods Appl. 1991 Nov;1(2):99–106. doi: 10.1101/gr.1.2.99. [DOI] [PubMed] [Google Scholar]
  18. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991 Oct 15;51(20):5520–5525. [PubMed] [Google Scholar]
  19. Oda T., Tsuda H., Scarpa A., Sakamoto M., Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 1992 Nov 15;52(22):6358–6364. [PubMed] [Google Scholar]
  20. Oesch F., Daly J. Conversion of naphthalene to trans-naphthalene dihydrodiol: evidence for the presence of a coupled aryl monooxygenase-epoxide hydrase system in hepatic microsomes. Biochem Biophys Res Commun. 1972 Feb 25;46(4):1713–1720. doi: 10.1016/0006-291x(72)90807-8. [DOI] [PubMed] [Google Scholar]
  21. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991 Nov 30;338(8779):1356–1359. doi: 10.1016/0140-6736(91)92236-u. [DOI] [PubMed] [Google Scholar]
  22. Patel P., Stephenson J., Scheuer P. J., Francis G. E. p53 codon 249ser mutations in hepatocellular carcinoma patients with low aflatoxin exposure. Lancet. 1992 Apr 4;339(8797):881–881. doi: 10.1016/0140-6736(92)90332-w. [DOI] [PubMed] [Google Scholar]
  23. Qian G. S., Ross R. K., Yu M. C., Yuan J. M., Gao Y. T., Henderson B. E., Wogan G. N., Groopman J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):3–10. [PubMed] [Google Scholar]
  24. Ross R. K., Yuan J. M., Yu M. C., Wogan G. N., Qian G. S., Tu J. T., Groopman J. D., Gao Y. T., Henderson B. E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 1992 Apr 18;339(8799):943–946. doi: 10.1016/0140-6736(92)91528-g. [DOI] [PubMed] [Google Scholar]
  25. Scorsone K. A., Zhou Y. Z., Butel J. S., Slagle B. L. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res. 1992 Mar 15;52(6):1635–1638. [PubMed] [Google Scholar]
  26. Sheu J. C., Huang G. T., Lee P. H., Chung J. C., Chou H. C., Lai M. Y., Wang J. T., Lee H. S., Shih L. N., Yang P. M. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res. 1992 Nov 1;52(21):6098–6100. [PubMed] [Google Scholar]
  27. Skoda R. C., Demierre A., McBride O. W., Gonzalez F. J., Meyer U. A. Human microsomal xenobiotic epoxide hydrolase. Complementary DNA sequence, complementary DNA-directed expression in COS-1 cells, and chromosomal localization. J Biol Chem. 1988 Jan 25;263(3):1549–1554. [PubMed] [Google Scholar]
  28. Wild C. P., Chapot B., Scherer E., Den Engelse L., Montesano R. Application of antibody methods to the detection of aflatoxin in human body fluids. IARC Sci Publ. 1988;(89):67–74. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES